A stronger signal favoring erlotinib was observed on subgroup analysis amongst patients with EGFR -activating mutations, though this failed to reach statistical significance in great part due to the fact that these patients constituted only 16.5% of the ITT population ( n = 161 patients) [ 82 ].
← all excerpts
Systemic Therapy for Operable NSCLC: A Review of the Literature and Discussion of Future Directions.
2
—
—
The sentences
Similarly, the SWOG 9900 trial, published in 2010, showed a trend toward improved OS with neoadjuvant carboplatin–paclitaxel chemotherapy in patients with stage IB-IIIA disease, though these results did not reach statistical significance, as the trial was closed early, due to adjuvant chemotherapy becoming the standard of care while the trial was still in process [ 9 ].